DOCSLIB.ORG

Monthly Healthcare Review July 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monthly Healthcare Review July 2017 Monthly Healthcare Review July 2017 IPOs The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month. Last Last Financing Financing Company Name HQ Location Description Lead Manager Date Size (Millions) Promore Pharma Owner and operator of a bio-pharmaceutical company developing therapeutic peptides for (PROMO) 6-Jul-17 Solna, Sweden treating local wounds and infections. 8.74 Undisclosed Network 1 Financial Operator of a molecular diagnostics company offering a DNA-based testing platform that Securities, Network Co-Diagnostics specializes in the development of probes for real-time PCR to its customers. It also 1 Securities, (CODX) 12-Jul-17 Sandy, UT develops a design and analytics software for DNA test designing. 7.07 WallachBeth Capital The company is engaged in the extraction and purification of heparin glycosaminoglycan NKF Pharmaceuticals and develops a controlled, traceable, and detectable process for the production of crude (603707) 13-Jul-17 Nanjing, China heparin. 67.22 Undisclosed NextCell Pharma Huddinge, (NEXTCL) 13-Jul-17 Sweden Provider of medical products for autoimmune and inflammatory diseases and transplants. 2.88 Undisclosed Akcea Therapeutics Developer of RNA-targeted antisense therapeutic products created to transform the lives of BMO Capital (AKCA) 14-Jul-17 Cambridge, MA patients with serious cardiometabolic lipid disorders. 175.00 Markets Provider of nutritional supplements and medical devices for the restoration of the ability to PharmaNutra (PHN) 18-Jul-17 Pisa, Italy articulate and movement in osteoarticular affections. Undisclosed Undisclosed Developer of innovative nanoparticle-based treatments created to treat ocular diseases BofA Merrill Lynch, Kala Pharmaceuticals affecting both front and back of the eye, such as dry eye disease and post-surgical ocular J.P Morgan (KALA) 20-Jul-17 Waltham, MA inflammation and pain. 90.00 Securities JP Morgan Chase & Co, Itaú Unibanco Montevideo, Developer, manufacturer, and distributor of advanced medicines for gastroenterology, Holding, Grupo Grupo Biotoscana 21-Jul-17 Uruguay respiratory disease, and immunology. 407.24 BTG Pactual BMO Capital Sienna Markets, Cowen and Biopharmaceuticals Westlake Provider of medical dermatology and aesthetics treatment therapies for the treatment of Company, J.P (SNNA) 27-Jul-17 Village, CA inflammatory skin conditions. 65.00 Morgan Securities Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 1 Monthly Healthcare Review July 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Company Name Financing HQ Location Round Description Financing Investor(s) Date Size (Millions) Developer of an online platform that matches patients' records with the world's largest knowledge-base of cancer trials and helps to Mendel.ai 1-Jul-17 San Francisco, CA Seed Round contact and enroll patients in clinical trials. Undisclosed SOSV Siegfried Holding Zofingen, (SFZN) 1-Jul-17 Switzerland PIPE Developer and manufacturer of pharmaceutical products. Undisclosed Norges Bank Lightspeed Venture Partners, LionBird, Developer of non-invasive electrical nerve stimulation medical devices Corundum Open Theranica 3-Jul-17 Netanya, Israel Early Stage VC created to treat migraines and other common illnesses. 6.00 Innovation Scottish Enterprise, TRI Cap, Strathtay Ventures, Braveheart Investment Selkirk, United Developer of nano-technology and gene therapy designed to treat Group, Brian Kennedy, Ryboquin 3-Jul-17 Kingdom Early Stage VC cancer. 2.02 Brian Souter Developer of optical diagnostic devices that offer artificially intelligent MobileODT 4-Jul-17 Tel Aviv, Israel Early Stage VC visual diagnostic tools to conduct visual inspections and detect cancer. 6.83 OrbiMed, Tristel Secondary Manufacturer of pharmaceutical products, including generic drugs, Transaction - hospital equipment, herbal medicines, food supplements, and other Mr. Marcelo Leite Teuto Pfizer 4-Jul-17 Anapolis, Brazil Private related products. Undisclosed Henriques Medicxi Ventures, JDRF T1D, McDonald's Ventures, Diasome Developer of novel and cell targeted therapies designed to treat Black Beret Life Pharmaceuticals 5-Jul-17 Cleveland, OH Later Stage VC diabetes and obesity. 30.00 Sciences Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 2 Monthly Healthcare Review July 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Company Name Financing HQ Location Round Description Financing Investor(s) Date Size (Millions) Seventure Partners, Shinsei Corporate Developer of a genetically enhanced bacteria that fights tumors and Investment, Novartis proliferates in the hypoxic core of solid tumors where it secretes the Pharma, Mitsubishi UFJ enzyme cytosine deaminase, turning a systemically administered pro- Capital, Innovation drug into a cytotoxic agent, which hollows out the tumor from the Network Corporation Anaeropharma Science 5-Jul-17 Tokyo, Japan Later Stage VC inside. 13.20 of Japan Direct Allergy 5-Jul-17 Erie, PA Early Stage VC Provider of immunotherapy treatments for allergy sufferers. 0.20 Undisclosed Investors Developer of blood-based cancer molecular diagnostics for patient Exosome Diagnostics 5-Jul-17 Waltham, MA Later Stage VC stratification and disease monitoring. 30.29 Undisclosed Investors Accelerator/ Hemotune 5-Jul-17 Zürich, Switzerland Incubator Developer of a medical device designed to purify blood. 0.13 Venture Kick GenePath Dx 5-Jul-17 Pune, India Angel Operator of a next generation diagnostics company. Undisclosed Undisclosed Investors Secondary Manufacturer and developer of disposable insulin kits designed to Petach-Tikvah, Transaction - improve the current meal-time insulin therapy by providing controlled Insuline Medical (INSL) 5-Jul-17 Israel Private and consistent insulin injection site treatment and stabilization. 0.13 Mr. Kfir Zilberman PE Growth/ Jawbone Health Hub 6-Jul-17 San Francisco, CA Expansion Provider of health-related hardware and software services. Undisclosed BlackRock California Capital ProMetic Life Sciences Developer of therapeutics products for fibrosis, anemia, neutropenia, Equity, Peter J. (PLI) 6-Jul-17 Laval, Canada PIPE cancer, and autoimmune disease/inflammation. 29.63 Thomson Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 3 Monthly Healthcare Review July 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Company Name Financing HQ Location Round Description Financing Investor(s) Date Size (Millions) Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, Gilde Healthcare, CICA, Legend Capital, Alfred Mann Foundation, Axonics Modulation Developer of an implantable neuromodulation technology designed NeoMed Management, Technologies 6-Jul-17 Irvine, CA Later Stage VC for the treatment of urinary and fecal dysfunction. 35.00 Undisclosed Investors Developer of biosensors for cellular biology research and screening, Innovation Works, Sharp Edge Labs 6-Jul-17 Pittsburgh, PA Seed Round and drugs for protein trafficking disorders. 2.17 Undisclosed Investors Provider of contract research services and manufacturer of biological Qiming Venture products, including recombinant proteins, monoclonal antibodies, and Partners, Undisclosed Sino Biological 6-Jul-17 Beijing, China Early Stage VC genetic vaccines, for drug R&D. 29.40 Investors The Kraft Group, Developer of a radiofrequency spectroscopy platform designed to Canepa Healthcare, Dune Medical Devices 6-Jul-17 Paoli, PA Later Stage VC detect microscopic residual cancer. 13.80 ATON Partners Developer and provider of a disease diagnosis technology that can Aperiomics 6-Jul-17 Ashburn, VA Angel simultaneously test for all pathogens. 0.06 Undisclosed Investors Provider of a software that targets all underlying causes of Alzheimer's Muses Labs 6-Jul-17 Raleigh, NC Early Stage VC with a goal to return individuals to normal cognitive function. 2.06 Undisclosed Investors Developer of a bedside monitoring system that detects and depicts variations in pressure across a patient's body to aid in the prevention Wellsense 6-Jul-17 Nashville, TN Later Stage VC of pressure ulcers. 6.30 Undisclosed Investors Auckland, New Accelerator/ Provider of an online booking platform intended to facilitate online Vensa Health 6-Jul-17 Zealand Incubator appointment booking to available healthcare services. 0.02 Vodafone Xone Source: Pitchbook Compiled by: Lea Keller and Morgan Reape 4 Monthly Healthcare Review July 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Company Name Financing HQ Location Round Description Financing Investor(s) Date Size (Millions) Adams
Load more

Recommended publications
  • 2Nd FCF Life Science IPO Report
    FCF Life Science Research 2nd Life Science IPO Report – Initial Public Offerings in Europe and the US Enterovirus Part of FCF Life Science Research Series FCF Overview European and US Life Science IPOs C r o s s - border IPOs of European Issuers in the US Life Science IPO Outlook Appendix: European Cross - border Issuances in the US 2 FCF Overview FCF seeks to provide Who We Are Capital Markets Capabilities and Services its clients with ▪ Specialized investment bank and financing specialist financing Private / Venture capital financing Private equity financing ▪ Advising public and private small / midcap companies Pre-IPO Growth capital financing (i) at the lowest cost, ▪ Advisor for structuring and placement of financing transactions: Initial Public Offering (IPO) pursued in tandem) – All instruments: Unbiased approach to all available corporate Equity / Capital increase Private Investment in (ii) with the highest Public Dual-track (IPO and Public Equity (PIPE) flexibility, financing instruments (no product selling approach), allowing alternative transaction Block trade for customized financing structures (iii) in the shortest Receivables financing / Working capital / Revolving – All investors: Close and trusted relationships with senior period of time, Short-term Factoring / ABS credit facility executives of virtually all relevant equity and debt investors Debt Borrowing base / Guarantees / (iv) with the highest – Fast process: Process management skills and direct / personal Inventory financing Letter of Credit closing proba- access to institutional debt and equity investors enable fast Bank loan facility / Promissory note bility, and with transactions Straight debt (Schuldscheindarlehen) Debt Long-term Sale-and-lease back High-yield / PIK bond (v) financing partners ▪ More than 100 transactions with a total placement volume in Debt Corporate bonds (public / (public / private) that integrate well excess of EUR 4.0 billion since foundation in 2005 private placement) Second lien financing into their strategy ▪ Approx.
    [Show full text]
  • DENVER CAPITAL MATRIX Funding Sources for Entrepreneurs and Small Business
    DENVER CAPITAL MATRIX Funding sources for entrepreneurs and small business. Introduction The Denver Office of Economic Development is pleased to release this fifth annual edition of the Denver Capital Matrix. This publication is designed as a tool to assist business owners and entrepreneurs with discovering the myriad of capital sources in and around the Mile High City. As a strategic initiative of the Denver Office of Economic Development’s JumpStart strategic plan, the Denver Capital Matrix provides a comprehensive directory of financing Definitions sources, from traditional bank lending, to venture capital firms, private Venture Capital – Venture capital is capital provided by investors to small businesses and start-up firms that demonstrate possible high- equity firms, angel investors, mezzanine sources and more. growth opportunities. Venture capital investments have a potential for considerable loss or profit and are generally designated for new and Small businesses provide the greatest opportunity for job creation speculative enterprises that seek to generate a return through a potential today. Yet, a lack of needed financing often prevents businesses from initial public offering or sale of the company. implementing expansion plans and adding payroll. Through this updated resource, we’re striving to help connect businesses to start-up Angel Investor – An angel investor is a high net worth individual active in and expansion capital so that they can thrive in Denver. venture financing, typically participating at an early stage of growth. Private Equity – Private equity is an individual or consortium of investors and funds that make investments directly into private companies or initiate buyouts of public companies. Private equity is ownership in private companies that is not listed or traded on public exchanges.
    [Show full text]
  • Chronix Biomedical Secures $1.6 Million in Financing
    Chronix Biomedical Secures $1.6 Million in Financing Led by Nation's Largest Angel Investor Network -- Keiretsu Forum LOS ANGELES, CA -- (MARKET WIRE) -- 05/24/2005 -- Keiretsu Forum, the nation's largest angel investor network, today announced its investment in Chronix Biomedical, an applied genomics company based in San Jose with research facilities in Göttingen, Germany. Chronix Biomedical has closed this round as a convertible note of $1.6 Million with Keiretsu Forum members investing $1.1 Million. The company develops products and services for the detection and monitoring of chronic diseases with particular focus on genomic-based assays that will be utilized in the emerging fields of "theranostics" and "pharmacogenetics." Chronix's first and second commercial products, the Göttingen Living Test (GLT) is a test for the detection of cows at risk for developing bovine spongiform encephalopathy (BSE) or mad cow disease and the humans' form of variant Creutzfeldt-Jakob disease (vCJD). Its third commercial product is a personalized medicine test for patients with human Myeloma, a cancer found in bone marrow cells. "Ultimately we see this as a simple way to evaluate and treat Myeloma at a molecular level," said Dr. Brian Durie, IMF Chairman of the Board and Director of Myeloma Programs, Aptium Oncology. "This is one way to bring treatment for Myeloma into the 21st Century." "We are very excited about the important work pioneered by Chronix Biomedical. This is a company that can make a real difference in the testing and treatment of Myeloma as well as Mad Cow Disease," explained John Dilts, President of the Los Angeles and Westlake Village Chapters of Keiretsu Forum.
    [Show full text]
  • State Strategies to Promote Angel Investment for Economic Growth*
    Contact: Chris Hayter, Program Director, Economic Development Social, Economic, and Workforce Programs Division 202/624-7833 February 14, 2008 State Strategies to Promote Angel Investment for Economic Growth* Executive Summary Governors are increasingly interested in entrepreneurship because of its key role in driving business innovation. While entrepreneurs face several common challenges, including developing business acumen and making connections with experts and mentors, often their greatest challenge is raising capital. Entrepreneurs’ emerging technologies are frequently viewed as too risky for banks, private equity firms and venture capitalists, yet many fledgling companies require more investment to grow than can be raised from friends and family. Angel investors are increasingly stepping in to fill this gap. Angel investors are wealthy individuals with business or technology backgrounds who provide entrepreneurs with capital, connections, and guidance. They provide early-stage financing in a space once occupied by venture capitalists, who now invest primarily in larger deals and more mature companies. Individual angels invest between $5,000 and $100,000 in local and regional ventures, primarily in high-technology sectors, giving their investments local impact. In the past decade, many angel investors have formed and joined groups because investing through groups offers several advantages, most notably a large and more diverse portfolio, access to expertise, and higher deal flow. States increasingly recognize the value of angel investments and are adopting policies to promote them. Some have created statewide networks to assist the formation of angel groups, link angel groups to share best practices, and help groups invest together in companies that need more funding than a single group can offer.
    [Show full text]
  • The Global Investment Banking Advisor for Asia
    The global investment banking advisor for Asia The global investment banking advisor for Asia September 2021 Experts in Asian M&A The global investment banking advisor for Asia 2021 marks 25 years of providing high-quality M&A advice Where we are Key facts We deliver global coverage for our clients from BDA’s own platform #1 Cross-border Asian sellside M&A advisor London 1996 Founded and led since then by the same team New York Seoul Shanghai Tokyo Bankers across three continents Hong Kong 100 Mumbai Ho Chi Minh City Singapore 9 Offices globally 2 Strategic partners Our services How we are organized We provide M&A advisory services for: Divestitures Acquisitions Capital raisings Chemicals Consumer Healthcare & Retail Debt advisory & restructuring transactions Valuations Industrials Services Technology 1 On the ground, with local relationships BDA Partners is #1 for Asian cross-border private sellside M&A No other firm has built the same scale, focus, connectivity and deal flow in Asia Private, cross-border Asian sellside transactions up to US$1bn EV of last five years (2016–2020) Highlights Rank Advisor # of Deals 80% of transactions involved either the sale/acquisition of an Asian asset, an Asian buyer or an Asian seller 1 34 80% of M&A transactions with BDA as sellside advisor 2 32 75% of M&A transactions were cross-border 3 31 60% of sale to a strategic buyer vs 40% of sale to financial sponsors 4 27 Long-established Asian presence 5 26 Coverage across Asia 60+ bankers in Asia 6 25 7 countries Seoul 2002 Tokyo 25 years of relationship- Shanghai 2002 1998 7 24 building Hong Kong 2000 8 22 Mumbai 2005 Ho Chi Minh City 2014 9 21 Singapore We reach Asian buyers 1996 10 19 120+ assets sold to Asian buyers 20,000+ calls made to Asian buyers 600+ transactions with Asian participation Note: (1) Target headquartered in China, India, Japan, Korea or Southeast Asia; Control transactions: i.e.
    [Show full text]
  • Annual Deal List
    Annual Deal List 16th annual edition Contents Section Page Mergers & Acquisitions 04 1. Domestic 05 2. Inbound 15 3. Merger & Internal Restructuring 18 4. Outbound 19 Private Equity 23 QIP 67 IPO 69 Disclaimer This document captures the list of deals announced based on the information available in the public domain. Grant Thornton Bharat LLP does not take any responsibility for the information, any errors or any decision by the reader based on this information. This document should not be relied upon as a substitute for detailed advice and hence, we do not accept responsibility for any loss as a result of relying on the material contained herein. Further, our analysis of the deal values is based on publicly available information and appropriate assumptions (wherever necessary). Hence, if different assumptions were to be applied, the outcomes and results would be different. This document contains the deals announced and/or closed as of 23 December 2020. Please note that the criteria used to define Indian start-ups include a) the company should have been incorporated for five years or less than five years as at the end of that particular year and b) the company is working towards innovation, development, deployment and commercialisation of new products, processes or services driven by technology or intellectual property. Deals have been classified by sectors and by funding stages based on certain assumptions, wherever necessary. Dealtracker editorial team Pankaj Chopda and Monica Kothari Our methodology for the classification of deal type is as follows: Minority stake - 1%-25% | Strategic stake - 26%-50% | Controlling stake - 51%-75% | Majority stake - 76%-99% Maps are for graphical purposes only.
    [Show full text]
  • LAEDC-IRG.Pdf
    table of contents What is Innovation? 4 “Innovate LA!” 4 What’s in the Guide 5 Technical Assistance Providers 6 Advanced Transportation Technologies and Energy Centers 6 AERO Institute 6 Business Technology Center of Los Angeles County 7 California Applied Biotechnology Centers 8 California Institute for Quantitative Biosciences 8 California Institute for Telecommunications and Information Technology 9 California Manufacturing Technology Consulting 9 California NanoSystems Institute 10 California Space Authority 10 Cal NASBO 11 CALSTART 11 Caltech/MIT Enterprise Forum Industrial Relations Center 12 Center for Advanced Transportation Technologies 12 Centers for Applied Competitive Technologies 13 Center for Information Technology Research in the Interest of Society 13 Center for International Trade Development 14 Center for Technology Commercialization 15 Center for Training, Technology and Incubation 15 Clearstone Venture Partners 16 College of the Canyons Advanced Technology Incubator 16 Digital Coast Roundtable 17 Entretech 17 Environmental, Health, Safety and Homeland Security Initiative 18 Fast Trac 19 Information Sciences Institute 19 Innovation Village 20 Keiretsu Forum Southern California 20 Los Angeles County Economic Development Corporation 21 Los Angeles Regional Technology Alliance 21 Los Angeles Venture Association 22 Multimedia and Entertainment Initiative 23 NASA Commercialization Center - AccelTech 23 NASA Far West Regional Technology Transfer Center 23 National Aeronautics and Space Administration (NASA) 24 National Science
    [Show full text]
  • Developing an Angel Investor Forum to Complement an Engineering School's Entrepreneurship Initiatives
    AC 2007-824: DEVELOPING AN ANGEL INVESTOR FORUM TO COMPLEMENT AN ENGINEERING SCHOOL'S ENTREPRENEURSHIP INITIATIVES Thomas Duening, Arizona State University Page 12.484.1 Page © American Society for Engineering Education, 2007 Developing an Angel Investor Forum to Complement an Engineering School’s Entrepreneurship Initiatives Page 12.484.2 Page Background After two years of decline, entrepreneurial activity in the United States increased from 10.5 percent in 2002 to 11.9 percent in 2003. This level of activity ranks the U.S. 7 th among 31 nations surveyed by the Global Entrepreneurship Monitor in Total Entrepreneurial Activity (TEA). 1 Importantly, the U.S. is the only nation among the G7 to register a TEA score in the top ten. Today, nearly 50 percent of the growth in the U.S. economy can be attributed to entrepreneurial activity; much of this activity is in the technology sector. Since success in a technology venture requires both technical feasibility and economic viability an engineering curriculum that integrates both aspects is of considerable value. 2 Of the over 200 thousand graduates of college engineering and science programs each year in the U.S., a growing proportion seek employment in entrepreneurial ventures or are starting their own ventures. This trend among engineering and science graduates requires “a new type of engineer, an entrepreneurial engineer, who needs a broad range of skills and knowledge above and beyond a strong science and engineering background.” 3 Companies around the world are actively seeking innovators who can solve business problems and assess risks, in addition to being technically proficient.
    [Show full text]
  • Proxy Statement
    September 8, 2021 To our shareholders: I am pleased to invite you to the 2021 Annual General Meeting of Shareholders (the "Annual General Meeting") of Quotient Limited (“Quotient”, the “Company” or "we", "us" and "our") to be held on October 29, 2021, at 9:00 a.m., local time, at Business Park Terre Bonne B1, Route de Crassier 13, 1262 Eysins, Switzerland. Information about the meeting is presented on the following pages. Details regarding admission to the meeting and the business that will be conducted are described in the accompanying Notice of Annual General Meeting (the "AGM Notice") and Proxy Statement. In accordance with the “notice and access” rules and regulations adopted by the Securities and Exchange Commission (the "SEC"), instead of mailing a printed, paper copy of our proxy materials to each shareholder who holds shares in street name (the “full set delivery” option), we are furnishing proxy materials to those shareholders over the Internet (the “notice only” option). A company may use either option, “notice only” or “full set delivery,” for all of its shareholders or may use one method for some shareholders and the other method for others. We believe the “notice only” process expedites shareholders’ receipt of proxy materials and reduces the costs and environmental impact of our Annual General Meeting. We will bear the entire cost of the solicitation. On or about September 8, 2021, we will begin mailing a notice (the "Notice of Availability") to our shareholders containing instructions on how to access online our Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed with the SEC on June 3, 2021 (our "Annual Report"), vote online, and receive paper copies of these documents for shareholders who so select, as well as a link containing instructions on how to vote by telephone.
    [Show full text]
  • Angel Investing: a Case Study of the Processes, Risk, And
    ANGEL INVESTING: A CASE STUDY OF THE PROCESSES, RISK, AND INTERNAL RATE OF RETURN by Geoffroy T. Roach A Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Business Administration UNIVERSITY OF PHOENIX December 2008 © 2008 by GEOFFROY T. ROACH ALL RIGHTS RESERVED ANGEL INVESTING: A CASE STUDY OF THE PROCESSES, RISK, AND INTERNAL RATE OF RETURN by Geoffroy T. Roach December 2008 Approved: Mark S. Allen, Ph.D., MBA, Mentor Alexander Hapka, Ph.D., Committee Member Eugene Lee, Ph.D., Committee Member Accepted and Signed: Mark S. Allen Nov 19, 2008 Accepted and Signed: Alexander Hapka Nov 19, 2008 Accepted and Signed: Eugene Lee Nov 19, 2008 __________________ Dawn Iwamoto, Ed.D. Date Dean, School of Advanced Studies University of Phoenix ABSTRACT One of the most difficult components in starting and growing a new enterprise is acquiring capital and other resources. Funding for many new enterprises comes from a large, yet relatively unidentified, group called angel investors. This case study is one of the few to examine the returns from angel investing and one of the first to examine the dynamics of angel investing groups. Computing internal rate of return for angel investments for Keiretsu Forum, an angel group, for the years 2000-2006 revealed that the investments generated higher returns than could have been obtained from the broader equity market as measured by popular index funds. Perhaps more important, this study also indicated that the processes developed by and regularly used by the angel group are effective at identifying potential failed deals and are not so restrictive as to bypass potential winners.
    [Show full text]
  • Building Michigan's Vibrant Future
    BUILDING2 MICHIGAN’S0 VIBRANT1 FUTURE1 “THESE GUYS CAN ADD A ZERO.” “WE’VE GROWN 43% OVER THE LAST TWO “WHEN I SAW THE RESULTS FROM THE AD CAMPAIGN, Josh Linkner, CEO and Managing Partner, YEARS. THEIR MADNESS WORKS.” I THOUGHT SOMEONE SCREWED UP PLACING A Detroit Venture Partners Tim Marshall, President, Bank of Ann Arbor DECIMAL POINT.” John Lichtenberg, CMO, Walsh College BRANDING THAT HITS. Perich Ad_VCA.indd 1 4/9/12 11:44 AM TABLE OF CONTENTS Executive Summary ...................................................................................3 Michigan Venture Capital Association................................................4 National and Midwest Venture Capital ..............................................6 Michigan Venture Capital Summary ................................................. 12 Michigan’s Successful Exits .................................................................. 30 Angel and Pre-Seed Summary ............................................................. 34 MVCA Activities .........................................................................................40 Michigan Venture Capital and Angel Network Directory ............................................................. 42 Photography by Leisa Thompson and Jeff Borisen. Helping entrepreneurs build great companies in the software, digital media, education technology and health information technology markets Michigan Office: 130 S. First Street, Suite 201 $250 MILLION IN CAPITAL Ann Arbor, MI 48104 UNDER MANAGEMENT PH: (734) 663-6500 www.mkcapital.com
    [Show full text]
  • Healthcare & Life Sciences
    HEALTHCARE & LIFE SCIENCES Industry Update │ May 2021 Healthcare & Life Sciences INDUSTRY UPDATE │ May 2021 Healthcare & Life Sciences Industry Overview QUICK TAKE: HEALTHCARE AUTOMATION Operating on tight margins and with lives at stake, healthcare providers are embracing automation as a way to ensure process quality while optimizing efficiency. Here, senior members of the Harris Williams Healthcare & Life Sciences Group share insights on the top considerations for investors exploring opportunities in the healthcare automation solutions sector, with a special focus on pharmacy automation. Read the article. M&A ENVIRONMENT ( 1 ) There have been roughly 625 M&A transactions in the healthcare and life sciences industry since the beginning of 2021, worth roughly $100 billion, compared with approximately $222 billion for all of 2020. Notable recent transactions include the acquisition of PPD Inc. (NasdaqGS: PPD) by Thermo Fisher Scientific Inc. (NYSE: TMO), Kindred Healthcare LLC by Humana Inc. (NYSE: HUM), and Luminex Corporation (NasdaqGS: LMNX) by DiaSorin SpA (BIT: DIA). PUBLIC COMPANY PERFORMANCE ( 1 ) Stock prices increased for many healthcare and life sciences companies during the past three months. In fact, the Harris Williams HCLS Composite Index increased 10.1%, while the S&P increased 12.6%. Notable sector increases include assisted living (increased 48.3%), healthcare staffing (increased 31.0%), and dental products (increased 21.8%). Industrywide stock prices have experienced increases as a whole; the HCLS Composite Index showed an increase over the past 12 months of 67.3%. At the category level, provider-based services grew by 67.7% on average over the past 12 months, followed by payor, provider, and pharmacy support services increasing 37.6% and products and devices stock prices increasing 35.4%.
    [Show full text]